![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://kalkinemedia.com/au/news/healthcare/brief-pharma-mar-gets-approval-of-zepzelca-for-treatment-of-metastatic-small-cell-lung-cancer-in-switzerland
https://pharmamar.com/en/pharmamar-initiates-first-human-clinical-trial-of-a-new-molecule-pm534-for-cancer-patients/
https://asebio.com/en/news-events/news/pharmamar-leads-oncoliberyx-consortium-together-four-research-centers-develop-new
https://www.reuters.com/markets/europe/spains-pharmamar-says-potential-covid-19-treatment-shows-efficacy-against-2022-01-11/
https://www.prnewswire.co.uk/news-releases/pharmamar-signs-a-new-licensing-and-commercialization-agreement-with-eczacibasi-for-lurbinectedin-in-turkey-826674247.html
https://www.prnewswire.com/news-releases/pharmamar-and-jazz-pharmaceuticals-announce-initiation-of-confirmatory-phase-3-clinical-trial-of-zepzelca-lurbinectedin-for-the-treatment-of-patients-with-relapsed-small-cell-lung-cancer-301442832.html
https://www.reuters.com/article/us-pharmamar-results/spains-pharmamar-posts-58-drop-in-9-mth-profit-despite-higher-revenues-idUSKBN2HI2DS
https://pharmamar.com/wp-content/uploads/2021/09/PR_PharmaMar_announces_the_Canada_approval_of_lurbinectedin_DEF.pdf
https://www.prnewswire.com/news-releases/new-therapy-to-treat-advanced-small-cell-lung-cancer-zepzelca-lurbinectedin-approved-in-singapore-301382325.html